1. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Issue 9 (5th April 2018) Authors: Ellingson, Benjamin M; Abrey, Lauren E; Nelson, Sarah J; Kaufmann, Timothy J; Garcia, Josep; Chinot, Olivier; Saran, Frank; Nishikawa, Ryo; Henriksson, Roger; Mason, Warren P; Wick, Wolfgang; Butowski, Nicholas; Ligon, Keith L; Gerstner, Elizabeth R; Colman, Howard; de Groot, John; Chang, Susan; ... Journal: Neuro-oncology Issue: Volume 20:Issue 9(2018) Page Start: 1240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. (11th November 2019) Authors: Lee, Eudocia; Chukwueke, Ugonma; Hervey-Jumper, Shawn; DeGroot, John; Leone, Pablo; Armstrong, Terri; Chang, Susan; Arons, David; Oliver, Kathy; Verble, Kay; Musella, Al; Willmarth, Nicole; Alexander, Brian; Bates, Amanda; Doherty, Lisa; Galanis, Evanthia; Gaffey, Sarah; Halkin, Thomas; Friday, B... Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. IMMU-19. PD-1 BLOCKADE ACTIVATES CD4 T CELLS AND THE INNATE IMMUNE RESPONSE FOR GLIOBLASTOMA ERADICATION. (5th November 2018) Authors: Speranza, Maria Carmela; Klein, Sarah R; Gokhale, Prafulla C; Wilkens, Margaret K; Jones, Kristen L; Chaudhri, Apoorvi; Kirschmeier, Paul T; Reardon, David; Freeman, Gordon Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. (5th November 2018) Authors: Touat, Mehdi; Dubuc, Adrian; Meredith, David; Tsuji, Junko; Mills, Caitlin; Gaffey, Sarah; Geduldig, Jack; Watkinson, Fiona; Pelton, Kristine; Malinowski, Seth; Lennon, Niall; Sorger, Peter; Trippa, Lorenzo; Ramkissoon, Shakti; Reardon, David; de Groot, John; Galanis, Evanthia; Welch, Mary; Nabor... Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). (5th November 2018) Authors: Reardon, David; Kaley, Thomas; Dietrich, Jorg; Clarke, Jennifer; Dunn, Gavin; Lim, Michael; Cloughesy, Tim; Gan, Hui; Park, Andrew; Schwarzenberger, Paul; Ricciardi, Toni; Macri, Mary; Ryan, Aileen; Venhaus, Ralph Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM). (5th November 2018) Authors: Khasraw, Mustafa; Weller, Michael; Estelles, David Lorente; Kolibaba, Kathryn; Lee, Chee; Gedye, Craig; De La Fuente, Macarena; Vicente, David; Reardon, David; Ojalvo, Laureen; Helwig, Christoph; Gourmelon, Carole; Groves, Morris Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. ACTR-17. EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY. (5th November 2018) Authors: Brenner, Andrew J; Reardon, David; Wen, Patrick; Huang, Shiliang; Fox, Peter; Muzi, Mark; Lee, Eudocia Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL. (5th November 2018) Authors: Prins, Robert; Mochizuki, Aaron; Orpilla, Joey; Lee, Alexander; Davidson, Tom; Gaffey, Sarah; Sanders, Catherine; Rytlewski, Julie; Ellingson, Benjamin; Li, Gang; Yong, William; Clarke, Jennifer; Arrillaga-Romany, Isabel; Colman, Howard; Reardon, David; Kaley, Thomas; de Groot, John; Liau, Linda;... Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA. (5th November 2018) Authors: Blandin, Anne-Florence; Graham, Maya; Ramkissoon, Shakti; Ramkissoon, Lori; Pelton, Kristine; Pages, Mélanie; Jones, Robert; Becker, Sarah; Watkinson, Fiona; Schoolcraft, Kathleen; Haemels, Veerle; Goumnerova, Liliana; Chi, Susan; Wright, Karen; Kieran, Mark; Tauziede-espariat, Arnault; Varlet, P... Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA. (5th November 2018) Authors: Ahluwalia, Manmeet; Peereboom, David; Schilero, Cathy; Forst, Deborah; Wong, Eric; Wen, Patrick; Reardon, David Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗